Join Growin Stock Community!

Immuron limitedIMRN.US Overview

US StockHealthcare
(No presentation for IMRN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IMRN AI Insights

IMRN Overall Performance

IMRN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IMRN Recent Performance

-1.30%

Immuron limited

0.05%

Avg of Sector

-0.31%

S&P500

IMRN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IMRN Key Information

IMRN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IMRN Profile

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.

Price of IMRN

IMRN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IMRN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.36
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.90
PB Ratio
1.08
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
63.82%
Net Margin
-71.12%
Revenue Growth (YoY)
13.26%
Profit Growth (YoY)
7.55%
3-Year Revenue Growth
91.64%
3-Year Profit Growth
82.59%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.36
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.90
PB Ratio
1.08
Price-to-FCF
-
Gross Margin
63.82%
Net Margin
-71.12%
Revenue Growth (YoY)
13.26%
Profit Growth (YoY)
7.55%
3-Year Revenue Growth
91.64%
3-Year Profit Growth
82.59%

  • When is IMRN's latest earnings report released?

    The most recent financial report for Immuron limited (IMRN) covers the period of 2026Q2 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IMRN's short-term business performance and financial health. For the latest updates on IMRN's earnings releases, visit this page regularly.

  • What is the operating profit of IMRN?

    According to the latest financial report, Immuron limited (IMRN) reported an Operating Profit of -2.26M with an Operating Margin of -55.14% this period, representing a growth of 10.79% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is IMRN's revenue growth?

    In the latest financial report, Immuron limited (IMRN) announced revenue of 4.11M, with a Year-Over-Year growth rate of 2.83%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does IMRN have?

    At the end of the period, Immuron limited (IMRN) held Total Cash and Cash Equivalents of 9.99M, accounting for 0.66 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does IMRN go with three margins increasing?

    In the latest report, Immuron limited (IMRN) did not achieve the “three margins increasing” benchmark, with a gross margin of 63.42%%, operating margin of -55.14%%, and net margin of -45.86%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IMRN's profit trajectory and future growth potential.

  • Is IMRN's EPS continuing to grow?

    According to the past four quarterly reports, Immuron limited (IMRN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.27. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IMRN?

    Immuron limited (IMRN)'s Free Cash Flow (FCF) for the period is -2.43M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 39.03% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.